EMA Authorised: Vimpat (lacosamide) — UCB Pharma SA

View source ↗

Summary

The European Medicines Agency granted authorisation for Vimpat (lacosamide) for epilepsy, with UCB Pharma SA as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Vimpat (lacosamide)

Snippet

Status: Authorised. Therapeutic area: Epilepsy. MAH: UCB Pharma SA. Decision date: 08/05/2025